首页> 外国专利> METHOD FOR PREDICTION OF LIVER FIBROSIS DYNAMICS IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1, NOT RESPONDING TO TREATMENT WITH PEGYLATED INTERFERONS AND RIBAVIRIN

METHOD FOR PREDICTION OF LIVER FIBROSIS DYNAMICS IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1, NOT RESPONDING TO TREATMENT WITH PEGYLATED INTERFERONS AND RIBAVIRIN

机译:预测不响应聚乙二醇干扰素和利巴韦林治疗的慢性丙型肝炎C基因患者的肝纤维化动力学的方法

摘要

FIELD: medicine.;SUBSTANCE: invention is intended to predict the reliability of the liver fibrosis dynamics in patients with HCV, genotype 1, not responding to two-component antiviral therapy with pegylated interferons and ribavirin. Blood group in combination with the study of IL28B gene polymorphism is determined, at that, in 100% of cases liver fibrosis progression was observed in patients with blood group Aβ (II) and one- or two-nucleotide substitution of cytosine by thymine (CT) in the rs 12979860 locus and one- or two-nucleotide substitution of thymine by guanine (TG) in the rs 8099917 locus of the IL28B gene.;EFFECT: method allows selection of patients for non-interferon therapy, which eliminates the negative dynamics of liver fibrosis for this category of patients and reduces the cost of treatment.;4 tbl
机译:领域:药物:本发明旨在预测基因型为1的HCV患者对聚乙二醇干扰素和利巴韦林的二组分抗病毒治疗无效的可靠性。确定血型与研究IL28B基因多态性相结合,在这种情况下,在血型Aβ(II)且胸腺嘧啶的一或二核苷酸取代胞嘧啶的患者中观察到100%的肝纤维化进展(C rs 12979860基因座中的> T)以及IL28B基因rs 8099917基因座中的鸟嘌呤的一个或两个核苷酸的胸腺嘧啶取代(T> G)。消除了这类患者的肝纤维化的不利影响,并降低了治疗成本。4

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号